A wholly owned subsidiary of Tris Pharma advancing cebranopadol, a first-in-class oral dual NOP/MOP receptor agonist, toward a US NDA filing in moderate-to-severe acute pain, with Greater China rights licensed to Zhejiang Conba Pharmaceutical.
A wholly owned subsidiary of Tris Pharma advancing cebranopadol, a first-in-class oral dual NOP/MOP receptor agonist, toward a US NDA filing in moderate-to-severe acute pain, with Greater China rights licensed to Zhejiang Conba Pharmaceutical.
